The drug sensitivities of human immunodeficiency virus (EHV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells. Fifty percent inhibitory dose (ID5o) values of 18 isolates from untreated individuals ranged between 0.01 FM and 0.05 FLM. In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID5o or ID95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in IDso. The latter isolates were also insensitive to 3'-azido-2',3'-dideoxyuridine; however, the isolates were still sensitive to 2',3'-dideoxycytidine, 2',3'-dideoxy-2',3'-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample ofpatients whether development ofa less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Z IDOVUDINE IS EFFECTIVE AGAINST
HIV in vitro and has been demonstrated to improve the quality and length of life of patients with AIDS and advanced ARC (1, 2) . Furthermore, serum levels of viral p24 antigen are reduced after initiation of drug treatment, suggesting a significant antiviral effect (3, 4) . However, dose reductions may be required because of an inability of patients to tolerate the drug (5, 6) . In addition, virus can be isolated during therapy even with current dose regimens (1, 4) , which indicates that zidovudine may not suppress virus production completely in vivo. The objective of the present study was to investigate whether prolonged exposure of HIV to zidovudine in patients might result in selection of variants with reduced drug sensitivity. Attempts to select such variants by passage in tissue culture have so far been unsuccessful (7) .
HIV isolation was attempted from 101 patients; 54 of these were receiving zidovudine therapy as a result of enrollment between March 1986 and July 1987 in three separate, controlled trials at the University ofCalifomia, San Diego. Isolates were made by co-cultivation of peripheral blood lymphocytes (PBLs) (8) , from patients before and during prolonged therapy, with cells of the continuous cell line MT-2 (9). Where isolation was successful, attempts were made to recover virus from PBLs stored before initiation of therapy. Forty-six high-titer virus stocks were produced from a total of 33 individuals, 21 of whom had received zidovudine for up to 30 months. Virus sensitivity data were obtained from 17 of those patients (2 of whom were treated for less than 6 months). Of the 46 isolates, 18 were from patients who had received no treatment at the time of isolation. The success rate for virus isolation from PBL samples, whether fresh or frozen, from treated or untreated individuals, was approximately 30% in each case.
A HeLa cell line (HT4-6C) expressing the human CD4 receptor on its surface (9) was used to establish an assay system for assess- AOOlA was obtained before treatment initiation and A001B after 12 months of therapy. A040A was a pretreatment isolate and A040B was obtained after 14 tion curve (Fig. 1) , with or without a shift in ID50, suggests the presence of a subfraction of insensitive variants in an otherwise sensitive population. Sensitivity profiles for paired isolates obtained before and during therapy from two of the individuals who displayed small changes in sensitivity are shown in Fig. 1A . In a similar example (Fig.  1B) , isolates from two patients who had received therapy for 13 to 14 months had higher ID95 values than two unrelated patients who had not received therapy.
In other cases the changes in ID50 values were considerably higher with one-third (5/ 15) of the patients showing more than 100-fold increases in ID50 after 6 months or more of therapy. More than two sequential isolates were made in four patients and in each case there appeared to be a progressive decrease in drug sensitivity over an extended period of time (Fig. 1, C and D, show two examples). The sensitivity data for most isolates (including all posttreatment isolates), correlating ID50 and ID95 values with duration of therapy, are collated in Fig. 2 . Many of the ID95 values were >10 ,uM, the upper limit for this assay system, since above this drug concentration cytotoxic effects preclude accurate determination of plaque numbers.
To confirm that these shifts of in vitro sensitivity were not attributable to an artifact of the modified HeLa cells, we measured the sensitivity by means of an assay based on inhibition of cytopathic effects in MT-2 cells (12). In these experiments, we used paired isolates from five individuals in whom the greatest increases in ID50 values had been observed in the HeLa system. The relative changes in sensitivity were similar (Table 2 ) and these were confirmed by measurement of p24 levels in culture supernatants from MT-2 cells. However, the absolute values for ID50 obtained in MT-2 were different from those in HeLa cells, a common observation when comparing different assay systems in which different cells, end points, and input multiplicities are used.
By means of the five paired isolates we asked whether the development of in vitro resistance to zidovudine extended to other anti-retroviral agents. Post-therapy isolates that were resistant to zidovudine were also resistant to 3'-azido-2',3'-dideoxyuridine (AZdU), a closely related compound; in contrast, the same isolates displayed sensitivities to 2',3'-dideoxycytidine(ddC), 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), and phosphonoformate (PFA) that were similar to those ofisolates obtained near the initiation of therapy, with the possible exception of the sensitivity of P022C to D4T ( Table 2) .
The most likely mechanism for decreased sensitivity to zidovudine would appear, on the basis of current knowledge, to be through mutation in the reverse transcriptase (RT) gene (13) . We therefore tested virion-associated RT from the five paired isolates for inhibition by zidovudine triphosphate (14) . These experiments revealed no apparent difference in the degree of inhibition, as the measured ID50 values all fell in the narrow range from 0.005 ,uM to 0.009 ,uM. These data suggested that no changes in affinity of the enzymes for zidovudine triphosphate had occurred. It remains possible that mutations in RT could result in a decreased rate of incorporation of the analog into DNA. More substantial amounts of RT from these isolates are currently being obtained, by expression of cloned RT genes in Escherichia coli, to facilitate detailed biochemical characterization of these enzymes.
Of the 17 patients who received therapy, six discontinued treatment in the first 6 months (five died within 18 months). Clinical data for the remaining 11 patients (treated for 15 months or more) are shown in Fig.  3 . Five of these yielded viruses with marked reductions in sensitivity (increase in ID50 values of 100-fold or more); two of the patients had received full-dose therapy throughout, and the remainder had reduced or interrupted dosing (Fig. 3A) . Less dramatic changes were seen in isolates from the remaining six patients (Fig. 3B) , all of whom received reduced or interrupted dosing schedules. At this stage we have insufficient data to know whether any particular pattem of therapy favors selection of less sensitive strains. Similarly, we do not know whether the amount of active virus replication is an important factor.
Experience with acyclovir, an established and successful treatment for herpes simplex virus (HSV) infections, has suggested that although resistance is rare it is more likely to develop in immunocompromised patients (16) . In this study most patients were profoundly immunocompromised, with low CD4 cell counts throughout their therapy (Fig. 3) there was an apparent early decrease in antigen level consistent with previous reports (1, 3), which had led to the belief that p24 antigen levels are correlated with virus replication. However, those patients who developed variants with marked reductions in sensitivity (for example, patients A012 and A018) had no consistent pattem of resurgent p24 antigen. Four of the 11 patients had no detectable p24 antigen throughout the study and two of the three patients who died had no detectable antigen for many months prior to death. A further question relates to the virulence and pathogenic potential of these variants, since in general all HSV variants resistant to acyclovir that have been characterized exhibit attenuation ofvirulence (18) . It remains to be determined whether a similar picture will emerge with HIV. Because of the gradual and progressive changes in the sensitivity of isolates from individual patients, alterations in clinical status with the emergence of resistant variants would be difficult to recognize. However, it is clear that appearance of such variants does not herald any sudden or rapid deterioration in clinical condition (Fig. 3) .
In summary, HIV isolates from a group of 15 patients who had received zidovudine therapy for the treatment of AIDS or ARC for periods of at least 6 months showed some reduction in sensitivity to zidovudine in vitro when compared to isolates from patients who had not received the drug. Virus was isolated from 30% of patients, and this may not be truly representative. However, since changes in sensitivity have only been observed in viruses isolated from patients on zidovudine therapy, and not in viruses from patients at similar stages of disease progression who have received no drug, it is reasonable to assume that the less sensitive variants have been selected by exposure of HIV to zidovudine in the patient rather than by any peculiar selection pressures in transformed lymphocytes used for virus isolation. This conclusion is further supported by the failure of isolates with reduced zidovudine sensitivity to show cross-resistance to several other anti-retroviral agents.
In the absence of a clear picture of the clinical implications of these observations, which will require additional laboratory and clinical studies, it would be premature to alter any of the treatment protocols for HIV-infected individuals. However, HIV isolates from additional patients involved in clinical trials, including those involving other anti-retroviral agents, should be closely monitored, and it will be important to examine the potential utility ofcombined therapies.
cultured after long-term frozen storage. Cultures were maintained in RPM1 1640, supplemented with 10% fetal bovine serum, antibiotics, 2% interleukin-2, and polybrene (2 ,ug/ml) and expanded by addition of fresh MT-2 cells when a cytopathic effect was observed (betwecn 4 and 14 days). HIV replication was confirmed by the detection of p24 antigen in culture supematants (p24 antigen detection kit, Abbott, Chicago, Illinois). Virus pools were prepared from infected cultures and stored in aliquots at -70°C. All drug sensitivities were determined with virus pools that had been passaged no more than twice from original cultures. 11. Inhibition ofplaque formation (foci ofmultinudeated giant cells) was determined by infecting monolayers of HeLa HT4-6C cells (10) with cell-free HIV preparations. The input inoculum was adjusted to give 100 to 300 plaques per well (in 24-well plates)
in the no-drug control cultures. Virus was allowed to adsorb for 1 hour at 37°C prior to the addition of inhibitor in the culture medium (Dulbecco's modification of Eagle's medium, containing 5% fetal bovine serum plus antibiotics). After 3 days of incubation, monolayers were fixed with 10% formaldehyde and stained with 0.25% crystal violet to visualize plaques. This staining procedure revealed obvious individual dense foci of multinucleated giant cells.
ID50 values were derived directly from plots of percent plaque reduction versus inhibitor concentration.
